SCHEMBL711010

SCHEMBL711010

C(/C=C/c1ccccn1)=C\c1ccc2[nH]ccc2c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 1/20 0.47
CTNNB1 P35222 1/20 0.42
WNT3A P56704 1/20 0.42
NPC1 O15118 2/20 0.42
GRIN2D O15399 1/20 0.42
GRIN3B O60391 1/20 0.42
GRIN1 Q05586 1/20 0.42
GRIN2A Q12879 1/20 0.42
GRIN2B Q13224 1/20 0.42
GRIN2C Q14957 1/20 0.42
GRIN3A Q8TCU5 1/20 0.42
MEN1 O00255 1/20 0.42
RAB9A P51151 1/20 0.42
KMT2A Q03164 1/20 0.42
ATM Q13315 1/20 0.42
IP6K1 Q92551 1/20 0.41
FAAH O00519 1/20 0.40
SNCA P37840 1/20 0.39
CYP2D6 P10635 1/20 0.38
SLC6A2 P23975 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL711011 1.00 CYP2A6 (0.47) CYP2A6CTNNB1WNT3ANPC1GRIN2D
SCHEMBL709076 0.91 CYP2A6 (0.50) CYP2A6CTNNB1WNT3ANPC1GRIN2D
SCHEMBL709077 0.91 CYP2A6 (0.50) CYP2A6CTNNB1WNT3ANPC1GRIN2D
SCHEMBL709590 0.89 CYP2A6 (0.47) CYP2A6NPC1MEN1RAB9AKMT2A
SCHEMBL709591 0.89 CYP2A6 (0.47) CYP2A6NPC1MEN1RAB9AKMT2A
SCHEMBL707637 0.79 CYP2A6 (0.50) CYP2A6NPC1MEN1RAB9AKMT2A
SCHEMBL707636 0.79 CYP2A6 (0.50) CYP2A6NPC1MEN1RAB9AKMT2A
SCHEMBL715859 0.79 RELA (0.52) NPC1MEN1RAB9AKMT2AATM
SCHEMBL715858 0.79 RELA (0.52) NPC1MEN1RAB9AKMT2AATM
SCHEMBL14972929 0.75 CYP2A6 (0.59) CYP2A6CTNNB1WNT3ANPC1GRIN2D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124625-B2 enhancing the expression of apoAI; prevention or therapy of dislipidemia SHIONOGI & CO., LTD. (JP) 2012-02-28 US disclosed
US-8053445-B2 Utilities of olefin derivatives SHIONOGI & CO., LTD. (JP) 2011-11-08 US disclosed
US-20090036457-A1 Utilities of olefin derivatives YAMAMORI TERUO 2009-02-05 US disclosed
US-20040242615-A1 Utilities of olefin derivatives SHIONOGI & CO., LTD. (JP) 2004-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040242615-A1 Utilities of olefin derivatives APOL1, NR1H2, APOB CYP2A6 213/4885CTNNB1 1126/4885WNT3A 1179/4885
US-20090036457-A1 Utilities of olefin derivatives APOL1, APOB, NR1H2 CYP2A6 173/4885CTNNB1 1016/4885WNT3A 1188/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.